KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Supernus Pharmaceuticals (SUPN) Cash & Current Investments (2016 - 2025)

Historic Cash & Current Investments for Supernus Pharmaceuticals (SUPN) over the last 15 years, with Q3 2025 value amounting to $281.2 million.

  • Supernus Pharmaceuticals' Cash & Current Investments fell 3026.96% to $281.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $281.2 million, marking a year-over-year decrease of 3026.96%. This contributed to the annual value of $453.6 million for FY2024, which is 7797.5% up from last year.
  • Per Supernus Pharmaceuticals' latest filing, its Cash & Current Investments stood at $281.2 million for Q3 2025, which was down 3026.96% from $522.6 million recorded in Q2 2025.
  • In the past 5 years, Supernus Pharmaceuticals' Cash & Current Investments ranged from a high of $522.6 million in Q2 2025 and a low of $151.7 million during Q2 2023
  • For the 5-year period, Supernus Pharmaceuticals' Cash & Current Investments averaged around $353.4 million, with its median value being $360.8 million (2022).
  • In the last 5 years, Supernus Pharmaceuticals' Cash & Current Investments crashed by 5796.52% in 2023 and then skyrocketed by 12893.06% in 2024.
  • Over the past 5 years, Supernus Pharmaceuticals' Cash & Current Investments (Quarter) stood at $339.7 million in 2021, then soared by 35.81% to $461.3 million in 2022, then tumbled by 44.75% to $254.9 million in 2023, then soared by 77.97% to $453.6 million in 2024, then tumbled by 38.02% to $281.2 million in 2025.
  • Its Cash & Current Investments stands at $281.2 million for Q3 2025, versus $522.6 million for Q2 2025 and $463.6 million for Q1 2025.